Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.57 |
| ▸ | MAP3K14 | Q99558 | 15/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30684918 | 0.84 | MAPKAPK2 (0.57) | MAPKAPK2MAP3K14ROCK1 | |
| SCHEMBL26270373 | 0.83 | MAPKAPK2 (0.56) | MAPKAPK2MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL25402204 | 0.82 | MAPKAPK2 (0.55) | MAPKAPK2MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL30219555 | 0.82 | MAPKAPK2 (0.55) | MAPKAPK2MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL26270376 | 0.82 | MAPKAPK2 (0.52) | MAPKAPK2MAP3K14CDC7CDK2ROCK1 | |
| SCHEMBL28986278 | 0.80 | MAPKAPK2 (0.56) | MAPKAPK2MAP3K14 | |
| SCHEMBL28986263 | 0.80 | MAPKAPK2 (0.56) | MAPKAPK2MAP3K14 | |
| SCHEMBL30219552 | 0.80 | MAPKAPK2 (0.56) | MAPKAPK2MAP3K14 | |
| SCHEMBL30219632 | 0.80 | MAPKAPK2 (0.56) | MAPKAPK2MAP3K14 | |
| SCHEMBL30219585 | 0.79 | MAPKAPK2 (0.55) | MAPKAPK2MAP3K14CDC7CDK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109810110-B | Compound with 2-aminopyrimidine structure, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-01-24 | — | — | CN | disclosed |